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Protein kinase C
PKCThe role of protein kinase C (PKC) isozymes in phorbol myristate acetate (PMA)-induced sphingosine 1-
phosphate (S1P) receptor 1 (S1P1) phosphorylation was studied. Activation of S1P1 receptors induced an imme-
diate increase in intracellular calcium, which was blocked by preincubation with PMA. Both S1P and PMA were
able to increase S1P1 phosphorylation in a concentration- and time-dependent fashion. Down-regulation of PKC
(overnight incubation with PMA) blocked the subsequent effect of the phorbol ester on S1P1 phosphorylation,
without decreasing that of the natural agonist. Pharmacological inhibition of PKC α prevented the effects of
PMA on S1P-triggered intracellular calcium increase and on S1P1 phosphorylation; no such effect was observed
on the effects of the sphingolipid agonist. The presence of PKCα and β isoforms in S1P1 immunoprecipitates was
evidenced byWestern blotting. Additionally, expression of dominant-negativemutants of PKCα or β and knock-
down of these isozymes using short hairpin RNA, markedly attenuated PMA-induced S1P1 phosphorylation. Our
results indicate that the classical isoforms, mainly PKC α, mediate PMA-induced phosphorylation and desensiti-
zation of S1P1.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Sphingosine 1-phosphate (S1P) is a bioactive sphingolipid metabo-
lite that mediates a plethora of actions at the levels of individual cells,
tissues and organisms [1]. This lipid modulates proliferation, promotes
survival, thus protecting against apoptosis, and increases motility, che-
motaxis and vesicular trafﬁcking among many other cellular effects
[1]. These actions are of cardinal importance in sustaining vascular de-
velopment, maturation and stability [2,3], as well as participating in
the control of osteoclast metabolism and bone homeostasis [4] and in
the regulation of muscle cell biology [5]. Particularly important is the
physiological role of a S1P concentration gradient between tissue inter-
stitium and blood that determines immune-cell trafﬁcking [6]. There is
also a dark side in S1P action because it is involved in pathological pro-
cesses such as ﬁbrosis [7] and cancer [8], among many others; such a
dark side is also a window of opportunity for therapeutic intervention.
Readers are directed to two special issues of Biochimica et Biophysica
Acta containing detailed reviews of speciﬁc actions (vol. 1781 (2008)
issue number 9, and vol. 1831 (2008) issue number 1).or 1; S1P, sphingosine-1-phos-
ein; GRK, G protein-coupled re-
, Ap. Postal 70-248,México D.F.
z).
ights reserved.The effects of S1P aremainlymediated through ﬁve G protein coupled
receptors, named S1P1–S1P5 [9]. Although current knowledge is far from
complete, evidence indicates that they are differentially expressed among
tissues and show differences in signaling and regulation [9,10]. S1P1 was
initially identiﬁed as an immediate-early gene induced during the mor-
phogenetic differentiation phase of angiogenesis [11] and subsequently
deorphanized as a S1P receptor [12]. It exerts its actions through pertussis
toxin-sensitive G proteins (mainly Gi), leading to inhibition of cyclic AMP
accumulation, activation of phosphoinositidase C, phosphoinositide 3-
kinase and calcium signaling [9,10]. It is the best studied at the levels of
structure [13] and function [9,10], and it is considered prototypic of this
receptor family [9,10].
S1P1 function is modulated by at least four types of posttranslational
modiﬁcations, i.e., sulfation [14], palmitoylation [15], ubiquitinylation
[16,17] and phosphorylation [12,17–19]. Sulfation takes place at the
receptor's amino terminus domain whereas the remaining modiﬁca-
tions occur at the intracellular third loop and carboxyl tail. It has been
observed that the lack of sulfation of two tyrosines of the extracellular
amino terminus domain of S1P1 diminishes high-afﬁnity S1P binding
and the functional action of this sphingolipid in T lymphocytes [14];
similar effects were observed expressing a non-sulfatable receptor mu-
tant (Y 19, 22 F) [14]. Palmitoylation/depalmitoylation reactions are
known to modulate the membrane expression and signaling of many
G protein-coupled receptors [20]. S1P1 palmitoylation of three cysteine
residues at the carboxyl tail takes place upon treatment with agonists
[15]; mutants in which such cysteines were exchanged for alanines
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naling and retarded internalization in response to agonists [15]. S1P1
polyubiquitinylation appears to be secondary to receptor phosphoryla-
tion and internalization and it is related with its proteasomal degrada-
tion [16]; a lysine at the carboxyl tail, (K341), has been identiﬁed as
the main (FTY720P) agonist-induced S1P1 ubiquitinylation site [17].
Phosphorylation appears to be a very early event associated with G
protein-coupled receptor desensitization and internalization, and G
protein-coupled receptor kinases (GRKs) and second messenger-
activated protein kinases play cardinal roles [21–23]. There is evidence
that desensitization and internalization of some G protein-coupled re-
ceptors can also occur in the absence of receptor phosphorylation [24].
Regarding phosphorylation and desensitization, it has been observed
that activated Akt/PKB binds and phosphorylates a threonine residue
(T236) of S1P1 which is not essential for Gi-dependent signaling but
appears to be required for downstream effects such as Rac activation,
chemotaxis and angiogenesis [19]. As in most systems, agonist-
induced S1P1 desensitization seems to involve GRKs. Agonist-induced
phosphorylation has been observed in several publications [12,17,18].
Watterson et al. [18] showed that S1P-induced S1P1 phosphorylation
takes place at serine and threonine residues and that GRK2 was able
to phosphorylate S1P1 in vitro; Arnon et al. [25] showed that residues
(T371, S374 and S375) are important in S1P-mediated receptor down
modulation and Oo et al. [17] determined, that three serine residues
(S336, S351 and S353), localized also in the carboxyl tail, were phos-
phorylated in response to the synthetic agonist, FTY720P. GRK2-
dependent S1P1 desensitization is of major importance in lymphocytes
for overcoming the attraction to blood induced by the S1P concentration
gradient [25].
It is also known that activation of protein kinase C, by active phorbol
esters, such as phorbol myristate acetate (PMA), can block the action of
S1P receptors [18,26] and it has been shown that PMA-induced S1P1
phosphorylation takes place at serine and threonine residues with an
important role of the carboxyl tail [18]. Although agonist- and PMA-
induced phosphorylations show great similarities, studies utilizing
truncated S1P1mutants have evidenced that these processes differ [18].
Protein kinase C (PKC) is a heterogeneous subfamily of protein ki-
nases comprising 10 isozymes that have been classiﬁed into three
groups based on their structure and cofactor regulation: a) conventional
PKCs including α, βI and βII (splice variants) and γ; b) novel PKCs, in-
cluding δ, ε, η and θ and c) atypical PKCs including ζ and λ [27]. There
is considerable evidence indicating that different PKC isoforms partici-
pate in the signaling, regulation and surface expression of S1P1
[18,26,28–30]. In the present work we employ different approaches to
deﬁne the PKC isoforms that participate in S1P1 phosphorylation and
desensitization; our results indicate that PKC αmediates these effects
and also suggests a lesser role of PKC β isoforms.
2. Materials and methods
2.1. Materials
Rosewell Park Memorial Institute medium (RPMI), trypsin, anti-
biotics, and other reagents used for cell culture were from Life Tech-
nologies. Fetal bovine serum was obtained from Multicell. S1P, PMA,
bis-indolylmaleimide I, hispidin, puromycin, DNA puriﬁcation kits,
and protease inhibitors were purchased from Sigma Chemical Co.
Gö 6976 and rottlerin were obtained from Calbiochem. [32P]Pi
(8500−9120 Ci/mmol) was obtained from PerkinElmer Life Sciences,
agarose-coupled protein Awas fromMillipore, and LY 333531mesylate
was fromAxonMedChem. Fura 2AMwas obtained from Invitrogen. The
plasmid for expression of S1P1 receptor fused to the green ﬂuorescent
protein (GFP) was generously provided to us by Dr. Timothy Hla (Uni-
versity of Connecticut Health Center) [31]. Plasmids for expression of
PKC α and β II dominant negative (DN) mutants [32] were purchased
from Addgene. Plasmids for expression of short hairpin RNA (shRNA)expression against human PKC α and β II (construct I, target sequence:
5′-GTCACAGTACGAGATGCAA-3′ and construct II, target sequence:
5′-CCAGGAAGTCATCAGGAAT-3′, respectively) using RNAi-Ready
pSiren-RetroQ vector (Clontech) were generous gifts from Drs. Mar-
tha Robles-Flores and María Cristina Castañeda-Patlán (Facultad de
Medicina, UNAM). Two additional shRNA plasmid constructs were
obtained from GeneCopoeia (construct III, target sequence: 5′-ATCGGC
TGTACTTCGTCAT-3′ and construct IV, target sequence: 5′-GGACGTTGTG
ATCCAAGAT-3′, respectively). Primary antibodies were obtained as
follows: anti-PKCα, -β I, -β II, -δ, -ε, -γ and -ζ and β-actin from
Santa Cruz Biotechnology, anti-GFP (monoclonal) and secondary anti-
bodies were from Zymed, nitrocellulose membranes from Bio-Rad and
chemiluminescence's kits were purchased from Pierce. Anti-GFP (rabbit
polyclonal) antisera used for immunoprecipitation were generated in
our laboratory [33,34]. Other reagents used were obtained from the
sources described [33,34].2.2. Cell lines and transfections for transient expression
Prostate cancer-derived LNCaP cells were obtained from American
Type Culture Collection (Manassas, VA, USA). These cells were selected
for the present work because they do not proliferate in response to S1P,
do not express S1P1 receptors and only express low amounts of the
remaining S1P receptors [35,36]; additionally, high expression of sphin-
gosine kinase I and S1P1 receptors is associated with chemotherapy-
resistance in prostate cancer cells [36] and participates in malignant pro-
gression [37], which renders these cells a context-relevant model. Cells
were transfected with the previously mentioned plasmid for expression
of the S1P1-GFP receptor, utilizing Lipofectamine 2000 following the
manufacturer's instructions andwere cultured for stable receptor expres-
sion in a selection media containing RPMI medium supplemented with
10% fetal bovine serum, 900 μg/ml of the neomycin analog, G-418 sulfate,
100 μg/ml streptomycin, 100 U/ml penicillin, and 0.25 μg/ml ampho-
tericin B at 37 °C under a 95% air/5% CO2 atmosphere. Several clones
were isolated and were screened for their responsiveness to S1P (in-
crease in intracellular calcium concentration) and GFP epiﬂuorescence.
A clone with robust response to S1P and epiﬂuorescence was selected
for this study and further cultured in the media described previously,
but with reduced G-418 (300 μg/ml). Despite the selection media, some
of the cells did not express the receptors as observed in images obtained
with epiﬂuorescence and confocal microscopes.
When the effect of expression of DN-PKC mutants was studied, cells
stably expressing S1P1-GFP were transfected (≈5 μg of plasmid for
each 10 cm-diameter dish) using Lipofectamine 2000, and were
employed 48–72 h after treatment. In experiments utilizing shRNA
against PKC isoforms, LNCaP cells were transfected as indicated previ-
ously with the plasmids (100–300 ng plasmid for each 3.5 cm-
diameter dish) and subjected to selection using puromycin (1 μg/ml).
Antibiotic-resistant cells were then transfected with the plasmid for ex-
pression of S1P1-GFP receptor and used 72 h later; receptor expression
was checked using ﬂuorescent microscopy.2.3. Intracellular calcium determinations
Intracellular calcium was determined essentially as previously de-
scribed [34]. In brief, cells were serum-starved overnight and then load-
ed with 2.5 μM of the ﬂuorescent Ca2+ indicator, Fura-2/AM, in Krebs-
Ringer-HEPES containing 0.05% bovine serum albumin, pH 7.4 for 1 h
at 37 °C and then washed three times to eliminate unincorporated
dye. Fluorescence measurements were carried out at 340 and 380 nm
excitation wavelengths and at 510 nm emission wavelength, with a
chopper interval set at 0.5 s, utilizing an AMINCO-Bowman Series 2 lu-
minescence spectrometer (Rochester, NY, USA). Intracellular calcium
([Ca2+]i) was calculated according to Grynkiewicz et. al. [38].
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The procedure was similar to those employed to study other recep-
tors fused to the GFP [33,34]. Brieﬂy, cells were maintained for 1 h in
phosphate-free medium without serum and then incubated in 1 ml of
the samemediumcontaining [32P]Pi (50 μCi/ml) for 3 h at 37 °C. Labeled
cells were stimulated as indicated, washed with ice-cold phosphate-
buffered saline, and solubilized with 0.5 ml of ice-cold buffer containing
50 mMTris–HCl pH 8.0, 50 mMNaCl, 5 mMEDTA, 1% TritonX-100, 0.1%
SDS, 10 mM NaF, 1 mM Na3VO4, 10 mM β-glycerophosphate, 10 mM
sodium pyrophosphate, 1 mM p-serine, 1 mM p-threonine, 1 mM p-
tyrosine, and protease inhibitors [33,34]. Cell lysates were centrifuged
at 12,700 ×g for 15 min at 4 °C and supernatants were incubated over-
night at 4 °C with protein A-agarose and anti-GFP antiserum generated
in our laboratory [33,34]. After two washes with 50 mM HEPES,
50 mM NaH2PO4, 100 mM NaCl, pH 7.2, 1% Triton X-100, 0.1% SDS, and
100 mM NaF, pellets containing the immune complexes were boiled
for 5 min in SDS-sample buffer containing 5% β-mercaptoethanol, and
subsequently subjected to SDS-polyacrylamide gel electrophoresis. The
gels were dried and the level of receptor phosphorylation was assessed
with a Molecular Dynamics PhosphorImager and ImageJ software
(NIH-USA). Data fell within the linear range of detection of the apparatus
and were plotted using Prism 5 from GraphPad software.
2.5. Western blot assays
Cells were washed with ice-cold phosphate-buffered saline and
lysed for 1 h in buffer containing NaCl 150 mM, Tris 50 mM (pH 7.4),
EDTA 1 mM and 1% Nonidet P40 on ice. Lysates were centrifuged at
12,700 ×g for 15 min and proteins in supernatants were separated by
electrophoresis on 10% SDS-PAGE. Proteins were electrotransferred
onto nitrocellulose membranes and immunoblottings were performed
using the samemembranes. Incubation with primary selective antibod-
ies was conducted for 12 h at 4 °C and with the secondary antibody for
1 h at room temperature. Super signal-enhanced chemiluminescence's
kits were employed exposing the membranes to X-Omat X-ray ﬁlms.Fig. 1. Effects of sphingosine-1-phosphate (S1P) on intracellular calcium concentration and S
(Δ[Ca2+]i) in cells challenged with the indicated concentration of S1P. Lower left panel: S1P1
Lower right panel: time-course of S1P1 phosphorylation in response to 1 μM S1P. Means are p
cells preparations. Representative autoradiograms are shown; B, Baseline.Signals were quantiﬁed by densitometric analysis utilizing the Scion
Image software from Scion Corporation.
In the coimmunoprecipitation studies S1P1-GFP was immuno-
precipitated as described for the receptor phosphorylation studies and
Western blotting was performed as indicated above.
2.6. Statistical analysis
Statistical analysis between comparable groups was performed
using ANOVA with Bonferroni's post-test and was performed with the
software included in the GraphPad Prism program. In the case of PKC
isoform down-regulation only two conditions were statistically com-
pared and this was performed employing the Student's t test. In all sta-
tistical comparisons p b 0.05 was considered signiﬁcant.
3. Results
In non-transfected LNCaP cells, 1 μM S1P induced an increase of in-
tracellular calcium of approximately 100 nM (from a baseline of
≈100 nM to≈200 nM)whereas in cells expressing S1P-GFP receptors,
the increase was signiﬁcantly larger,≈175–200 nM; in both cell lines
the effect of S1P was blocked by 1 μM PMA (see Supplementary
Fig. S1). The effect of S1P was concentration-dependent reaching its
maximum at 1 μM, and with an EC50 value of≈100 nM (Fig. 1, upper
panel). The magnitude of the response and its speed (slope) increased
in direct relationship to the agonist concentration used and after a
brief maximum peak, the intracellular calcium concentration decreased
to an above-baseline plateau that was also concentration-related. In
some of the tracings, a second transient and small increase was ob-
served during the plateau (representative tracings are presented in Sup-
plementary Fig. S2).
Untransfected cells (wild type) and those transfectedwith the GFP or
with the S1P1-GFP receptor construct were subjected tometabolic label-
ingwith Pi, GFP-immunoprecipitation and anti-GFPWestern blotting. As
depicted, in a representative Western blot (Fig. 2 bottom panel), only
faint, unspeciﬁc bands were detected in immunoprecipitates from1P1-GFP phosphorylation. Upper panel: increases in intracellular calcium concentration
phosphorylation in cells incubated for 15 min with the indicated concentration of S1P.
lotted with vertical lines representing the S.E.M. of 4 to 6 determinations using different
Fig. 2.Representative autoradiogramof S1P1-GFP phosphorylation andWestern blot using
a primary anti-GFP antibody. Non-transfected (WT) cells and cells transfected with the
GFP or the S1P1-GFP construct were used and stimulated with no agent (vehicle), 1 μM
S1P or 1 μM PMA. The estimated Mr are indicated on the left margin and on the right
one the location of S1P1-GFP, IgG heavy chains and GFP.
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or with the receptor construct, conspicuous bands were detected at
Mr ≈ 30 kDa and 75–80 kDa, respectively. It can be observed (Fig. 2,
upper panel) that S1P1-GFP (but not GFP) is a phosphoprotein whoseFig. 3. Effects of phorbol myristate acetate (PMA) on S1P-triggered intracellular calcium concen
indicated concentration of PMA for 5 min and then challenged with 1 μM S1P; the increases i
course of S1P1 phosphorylation in response to 1 μMPMA. Lower right panel: S1P1 phosphorylat
ted with vertical lines representing the S.E.M. of 4 to 6 determinations using different cells prephosphorylation state is increased in S1P- or PMA-treated cells. This
clearly indicates that it is the receptor in the construction, and not the
tag, which is subjected to phosphorylation.
The S1P concentration-response curve and the time-course of S1P1-
GFP phosphorylation are presented in Fig. 1 (bottom panels). S1P in-
duced a rapid receptor phosphorylation that reached its maximum
within 5–10 min and remained at this level for up to 30 min.Maximum
receptor phosphorylation was observed at 10 μMwith an EC50 value of
≈450 nM.
PMA alone did not alter baseline intracellular calcium concentration.
However, preincubation for 5 min with this active phorbol ester mark-
edly inhibited S1P-induced calcium response, in a concentration-
dependent fashion (Fig. 3, upper panel; representative calcium tracings
are shown in Supplementary Fig. S3). Maximal effect was observed at
1 μM PMA with an IC50 value of 10 nM. PMA-induced S1P1-GFP phos-
phorylation was evident as early as 2 min after its addition and contin-
ued increasing during the 30 min studied. Concentration-response
studies demonstrated that the maximal effective concentration was
100 nMwith an EC50 value of≈10 nM (Fig. 3).
It is well known that prolonged incubationwith PMA leads to deple-
tion (down-regulation) of some PKC isozymes. Experiments in which
cells were incubated overnight with 1 μM PMA showed that the PMA-
induced S1P1-GFP phosphorylation was markedly attenuated but in
contrast, S1P-induced phosphorylation was even larger than that ob-
served in cells preincubated overnight without the phorbol ester
(Fig. 4). To acquire some insight on the PKC isoforms involved, cell ly-
sates were subjected to electrophoresis and Western blotting utilizing
selective PKC antibodies. It was observed that overnight incubation
with PMA decreases the total immunodetected amount of PKC α to
only 16%, PKC β I to 12%, PKC β II to 9%, PKC δ to 28% and PKC ε to 23%
(Fig. 4); PKC γ also decreased, but showed greater variation, and it
was not statistically signiﬁcant. In sharp contrast, the immunodetected
amount of PKC ζ was not altered at all by the overnight treatment
with PMA; the amount of immunodetected β-actin was used as a con-
trol and it was unaltered by the phorbol ester treatment (Fig. 4).tration and on S1P1-GFP phosphorylation. Upper panel: cells were preincubated with the
n intracellular calcium concentration (Δ[Ca2+]i) were quantiﬁed. Lower left panel: time-
ion in cells incubated for 15 minwith the indicated concentration of PMA.Means are plot-
parations. Representative autoradiograms are shown; B, Baseline.
Fig. 4. Effect of down-regulation of PKC isozymes on S1P1-GFP phosphorylation. Left panel: cells were incubated in the absence or presence of 1 μMPMA overnight (o–n, 16–18 h)washed
and subjected to the phosphorylation protocol indicated underMaterial andMethods; cells were incubated for 15 min in the absence (B) or presence of 1 μMS1P or PMA.Means are plot-
tedwith vertical lines representing the S.E.M. of 4 to 6 determinations using different cells preparations. Representative autoradiograms (32P) and anti-GFPWestern blots (WB) are shown.
⁎p b 0.001 vs. their Baseline (B); ⁎⁎p b 0.001 vs. its Baseline (B) and p b 0.05 vs. PMA of cells preincubated overnight without the phorbol ester. Right panels: inmmunodetected PKC iso-
forms in extracts from cells incubated overnight in the absence (B) or presence of 1 μMPMA (PMA o-n). Densitometric analysis ofWestern blots was performed and the results were nor-
malized with the level of β-actin (PKC isoform/β-actin ratios). Means are plotted with vertical lines representing the S.E.M. of 3 determinations using different cells preparations.
Representative Western blots are shown. ⁎p b 0.001 vs. absence of PMA overnight (B).
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lysophosphatidic acid and bradykinin to increase intracellular calcium
concentration, which did not allow us to further study this parameter.
A pharmacological approach was used employing a general PKC in-
hibitor (bis-indolylmaleimide I) and the following available isoforms-
selective PKC inhibitors: PKCα and β (Gö 6976) [27,39,40], β (hispidin)
[41] and δ (rottlerin) [42]. These agents were tested at a 1 μM concen-
tration, based on preliminary experiments. The potent inhibitor LY
333531 was also tested, but at a concentration of 100 nM; this com-
pound shows some selectivity for PKC β but also inhibits PKC α [43].
None of these inhibitors altered baseline intracellular calcium; hispidin,
LY 333531 and rottlerin marginally increased the S1P1-GFP phosphory-
lation state (Supplementary Fig. S4). Interestingly, PMA-induced block-
ade of S1P-triggered intracellular calcium increase, was completely
prevented by cell pretreatment with bis-indolylmaleimide I or Gö
6976 (Fig. 5, upper panel); LY 333531 partially prevented PMA effect
and the remaining inhibitors were ineffective (Fig. 5, upper panel). Rep-
resentative calcium tracings are presented in Supplementary Fig. S5.
Consistentwith this, it was observed that PMA-induced S1P1-GFP phos-
phorylation was blocked by pretreatment with bis-indolylmaleimide I
or with Gö 6976 (Fig. 5, lower panel) whereas the action of the other in-
hibitors was statistically insigniﬁcant. The possibility that these inhibi-
tors could alter S1P-triggered intracellular calcium increase or agonist-induced S1P1 phosphorylation was tested, but no signiﬁcant action
was observed (Supplementary Fig. S6). We conﬁrmed that hispidin
was active using C9 cells expressing LPA1 receptors [33]. In these cells
PMA blocks lysophosphatidic acid-triggered increases in intracellular
calcium and preincubation with 1 μM hispidin was able to reduce by
50% the action of PMA. We next explored the possibility that PKC α
and -β isoforms might associate with the receptor. Western blotting
showed that PKC isoforms α, β I, and to a much lesser extent, β II,
coimmunoprecitated with S1P1-GFP receptor in the baseline state;
thiswas increased by cell treatmentwith PMA. Thedatawere consistent
for isoform α, those for the β I isozyme showed much more variation,
and the low detection of the β II isoform rendered it very difﬁcult to de-
tect any real change (Supplementary Fig. S7).
Expression of DN-mutants of PKC isoforms and shRNA technology
targeting sequences in these enzymeswas employed next. As illustrated
in Fig. 6 (upper panel) the DN mutants of both PKC α and -βmarkedly
decreased PMA-induced S1P1-GFP phosphorylation. No clear increases
in PKC expression was detected using PKC α/βII immunoprecipitation
andWestern blotting; however, taking advantage of the hemagglutinin
tag present in theDN-mutant plasmid constructions expression of these
proteins was evidenced in the same immunoprecipitates (Supplemen-
tary Fig. S8). The action of shRNA was conﬁrmed in cell extracts by
Western blotting against PKC α and β II; it was observed that shRNA
Fig. 5. Effect of PKC inhibitors on the action of PMA on S1P-triggered intracellular calcium
increases and S1P1-GFP phosphorylation.Upper panel: cellswere preincubated for 30 min
in the absence of any agent (open bars) or presence of 1 μMGö 6976 (Gö), 1 μMhispidin
(HIS), 100 nM LY 333531 (LY), 1 μM rottlerin (ROTT) or 1 μM bis-indolylmaleimide I
(BIM); where indicated 1 μM PMA was added during the last 5 min of this incubation.
At the end of this period cells were challengedwith 1 μMS1P and the increase in intracel-
lular calcium recorded.Means are plottedwith vertical lines representing the S.E.M. of 5–7
determinations using different cell preparations. ⁎p b 0.001 vs. S1P without PMA
preincubation; ⁎⁎p b 0.001 vs. S1P preincubated with PMA; ⁎⁎⁎p b 0.05 vs. S1P preincu-
bated with PMA. Lower panel: cells were preincubated for 30 min in the absence of any
agent or presence of 1 μM Gö 6976 (Gö), 1 μM hispidin (HIS), 100 nM LY 333531 (LY),
1 μM rottlerin (ROTT) or 1 μM bis-indolylmaleimide I (BIM); where indicated 1 μM
PMAwas added and cells were incubated for an additional 15 min period to study recep-
tor phosphorylation. Means are plotted with vertical lines representing the S.E.M. of 5–7
determinations using different cell preparations. A representative autoradiogram is
shown. ⁎p b 0.001 vs. Baseline (B); ⁎⁎p b 0.001 vs. PMA without any inhibitor.
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isozymes, but only partially (≈60%, Supplementary Fig. S9 upper
panel). The other two shRNA constructs (III and IV) were also able to
knock down their respective target PKC isozyme but altered the expres-
sion of the other isoform studied (Supplementary Fig. S9, lower panel).
These treatments reduced PMA-induced S1P1-GFP phosphorylation
(Fig. 6, lower panels). It was also observed that expression of shRNA
constructs III and IV increased basal S1P1-GFP phosphorylation (Fig. 6,
lower right panel). Expression of DN-mutants and shRNAs decreased
the cell calcium response to S1P but PMA was still able to further de-
crease such effects (data not shown).
The ability of PMA to induce S1P1 internalization has been reported
previously [18] and it was conﬁrmed in our work (Supplementary
Fig. S10). After an incubation of 15 min with 1 μM PMA, S1P1-GFP ﬂuo-
rescencewasno longerwell-deﬁned at the level of the plasmamembrane
and concomitantly an increase in signal was detected in intracellular ves-
icles (Supplementary Fig. S10).
4. Discussion
Our present work conﬁrms previous observations indicating that
PMA-activated PKC leads to phosphorylation and desensitization of
S1P1 receptors and deﬁnes that classical PKC isoforms, in particular
PKC α, mediate these effects. This conclusion is supported by results
employing different pharmacological and molecular biological tools.However, despite the various approaches utilized, the data do not
allow us to conclude that a single PKC isozymemight mediate these ef-
fects, but rather, they suggest that several classical isoforms participate
in these, exerting overlapping functions. This is not surprising because
the speciﬁc substrate sequence motifs for these PKC isoforms are re-
markably similar [44].
Our experiments using prolonged (overnight)-incubation with PMA
demonstrated that the strongest down-regulation (85–90%) took place
with classical PKC α, -β I and -β II rather than with the remaining iso-
forms, and this was associated with a nearly total decrease in the ability
of PMA to induce S1P1-GFP phosphorylation.
The use of available pharmacological PKC inhibitors indicated that
the broad spectrum PKC inhibitor, bis-indolylmaleimide I, and Gö
6976, with selectivity for the α and β isoforms [27,39,40], were able to
completely block PMA-induced S1P1-GFP phosphorylation, and addi-
tionally, to abolish the ability of PMA to inhibit S1P-triggered intracellu-
lar calcium increase. LY 333531 was only partially capable of blocking
the actions of PMA and the remaining inhibitors, hispidin and rottlerin,
were ineffective. The data strongly suggest a major role of PKC α in
these actions.
Work by other authors [18] has shown that PMA-induced S1P1 phos-
phorylation is completely blocked by the general PKC inhibitor bis-
indolylmaleimide I (alternative name GF 109203X), which is consistent
with our ﬁndings. However, these authors observed that the PMA effect
was only partially blocked by Gö 6976 and it was also partially inhibited
by 10 μMrottlerin [18]. The reasons for the differences of thisworkwith
our study are not clear, but could be explained on the basis of experi-
mental conditions, such as the drug concentrations and cell lines used.
To further test our ﬁndings, the effect of expression of DNmutants of
PKC isoforms was tested [32]. In our experiments DN mutants of both
PKC α and -βmarkedly diminished, although none of them abolished,
PMA-induced S1P1-GFP phosphorylation. It should be mentioned that
the possibility that these mutants could affect the action of more than
one isoform cannot be ruled out. Similar results were obtained with
the use of shRNAs, i. e., expression of the shRNA constructs was able
to partially block the S1P1 receptor phosphorylation induced by activa-
tion of PKC. In this regards it has been observed that activation of S1P1
induces ERK 1/2 phosphorylation which is inhibited by PKC α and -β I
siRNA [30]. Our data clearly evidenced a major role of PKCα in S1P1 re-
ceptor phosphorylation and desensitization. The possibility that PKC β
could participatewas suggested by someof the data. However,were un-
able to obtain solid evidence that unambiguously demonstrates a role of
this PKC isoform. A major problem was that genetic manipulation of
these cells altered the calcium response to S1P and in some cases in-
creased basal S1P1 receptor phosphorylation. This could have resulted
from off-target effects of the treatments or from compensatory actions,
but independently of the mechanism(s) involved, made very difﬁcult
data interpretation.
Coimmunoprecipitation studies indicated that more than one PKC
isozyme associated with S1P1-GFP, although that of PKC α was more
consistently observed. It was surprising that the PMA-promoted
interaction was not immediate but took several minutes. Certainly,
coimmunoprecipitation does not necessarily indicate direct physical
contact between S1P1 and the enzyme; this can take place through dif-
ferent associated entities. Assembly of a signaling complex has been
previously observed among S1P1, vascular endothelial growth factor re-
ceptor 2 and PKCα, in thyroid carcinoma cells [30]. Therefore, consider-
ing all of these data, we suggest that classical isoforms, mainly PKC α
and to a lesser extent PKC βmediate phosphorylation of S1P1.
S1P1-GFP phosphorylation and functional desensitization appear to
occur in parallel. Although endogenous receptors partially mediate the
S1P-triggered calcium response, receptor transfection was able to sig-
niﬁcantly increase it. The total S1P-elicited response was practically
obliterated by treatment with PMA, but pretreatment with a general
PKC inhibitor (bis-indolylmaleimide I) or a PKC α- and β-selective one
(Gö 6976), but not with a β-isoform-selective blocker (hispidin),
Fig. 6. Effect of expression of dominant-negative (DN) PKC mutants and shRNA constructs on PMA-induced S1P1-GFP phosphorylation. Upper panel: cells transfected with the DN-PKC
mutantswere subjected to the phosphorylation protocol incubating themduring the last 15 min in the absence of any agent (B) orwith 1 μMPMA (PMA).Means are plottedwith vertical
lines representing the S.E.M. of 4–5 determinations using different cells preparations. A representative autoradiogram is shown. ⁎p b 0.001 vs. its Baseline (B); ⁎⁎p b 0.05 vs. its Baseline
(B) and p b 0.005 vs PMA vector; ⁎⁎⁎p b 0.005 vs. PMA vector. Lower panels: cells transfected with the shRNA constructs I and II (left panel) or constructs III and IV (right panel) were
subjected to the phosphorylation protocol incubating them during the last 15 min in the absence of any agent (B) or with 1 μM PMA (PMA). Means are plotted with vertical lines
representing the S.E.M. of 4–5 determinations using different cells preparations. Representative autoradiograms are shown. ⁎p b 0.001 vs. its Baseline (B); ⁎⁎p b 0.05 vs. its Baseline
(B) and p b 0.005 vs. PMA vector; p b 0.005 vs. PMA vector.
333M.A. Morquecho-León et al. / Biochimica et Biophysica Acta 1843 (2014) 327–334avoided the action of the phorbol ester. These data suggest an important
role of PKCα in the regulation of S1P signaling in these cells. It is worth
mentioning that PKC is a major participant in signaling processes trig-
gered by a large variety of hormones, neurotransmitters and autacoids,
acting through G protein-coupled receptors and also receptor tyrosine
kinases [27]. Therefore, at least potentially, some of these agents
might modulate the action of S1P1 receptors. Considering the large
amount of physiological and pathophysiological processes in which
these receptors are involved [9,10] elucidation of the molecular entities
involved in the regulation seems to be relevant.
In agreement with previous ﬁndings [18], our present data indicates
that S1P-induced S1P1-GFP phosphorylation is mainly mediated
through a process that does not require PKC, likely involving GRKs
[17,18,25]. S1P1 phosphorylation sites have been deﬁned under the ac-
tion of the synthetic agonist FTY720P (mainly at serine residues 336,
351 and 353); such phosphorylation seems to proceed and could likely
be involved in internalization, poly-ubiquitinylation and degradation of
this receptor [17]. The study of the molecular participants that mediate
the phosphorylation/dephosphorylation cycles of S1P1 has potential im-
portance in physiology and physiopathology; our work participates in
the efforts to decipher them.
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